Circulating MicroRNAs as Novel Biomarkers for Platelet Activation
Open Access
- 15 February 2013
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation Research
- Vol. 112 (4), 595-600
- https://doi.org/10.1161/circresaha.111.300539
Abstract
Rationale: MicroRNA (miRNA) biomarkers are attracting considerable interest. Effects of medication, however, have not been investigated thus far. Objective: To analyze changes in plasma miRNAs in response to antiplatelet therapy. Methods and Results: Profiling for 377 miRNAs was performed in platelets, platelet microparticles, platelet-rich plasma, platelet-poor plasma, and serum. Platelet-rich plasma showed markedly higher levels of miRNAs than serum and platelet-poor plasma. Few abundant platelet miRNAs, such as miR-24, miR-197, miR-191, and miR-223, were also increased in serum compared with platelet-poor plasma. In contrast, antiplatelet therapy significantly reduced miRNA levels. Using custom-made quantitative real-time polymerase chain reaction plates, 92 miRNAs were assessed in a dose-escalation study in healthy volunteers at 4 different time points: at baseline without therapy, at 1 week with 10 mg prasugrel, at 2 weeks with 10 mg prasugrel plus 75 mg aspirin, and at 3 weeks with 10 mg prasugrel plus 300 mg aspirin. Findings in healthy volunteers were confirmed by individual TaqMan quantitative real-time polymerase chain reaction assays (n=9). Validation was performed in an independent cohort of patients with symptomatic atherosclerosis (n=33), who received low-dose aspirin at baseline. Plasma levels of platelet miRNAs, such as miR-223, miR-191, and others, that is, miR-126 and miR-150, decreased on further platelet inhibition. Conclusions: Our study demonstrated a substantial platelet contribution to the circulating miRNA pool and identified miRNAs responsive to antiplatelet therapy. It also highlights that antiplatelet therapy and preparation of blood samples could be confounding factors in case-control studies relating plasma miRNAs to cardiovascular disease.Keywords
This publication has 15 references indexed in Scilit:
- Prospective Study on Circulating MicroRNAs and Risk of Myocardial InfarctionJournal of the American College of Cardiology, 2012
- MicroRNAs in Vascular and Metabolic DiseaseCirculation Research, 2012
- Analytical challenges and technical limitations in assessing circulating MiRNAsThrombosis and Haemostasis, 2012
- Profiling of circulating microRNAs: from single biomarkers to re-wired networksCardiovascular Research, 2011
- Aspirin has little additional anti‐platelet effect in healthy volunteers receiving prasugrelJournal of Thrombosis and Haemostasis, 2011
- Clopidogrel Versus Dipyridamole in Addition to Aspirin in Reducing Embolization Detected With Ambulatory Transcranial DopplerStroke, 2011
- Plasma MicroRNA Profiling Reveals Loss of Endothelial MiR-126 and Other MicroRNAs in Type 2 DiabetesCirculation Research, 2010
- Circulating MicroRNAs in Patients With Coronary Artery DiseaseCirculation Research, 2010
- Proteomic analysis reveals presence of platelet microparticles in endothelial progenitor cell culturesPublished by American Society of Hematology ,2009
- Circulating microRNAs as stable blood-based markers for cancer detectionProceedings of the National Academy of Sciences of the United States of America, 2008